Clinical Trials Logo
  1. Home
  2. Multiple Organ Failure
  3. NCT06340269

Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in ACLF — MexACLF  

Multiple Organ Failure Clinical Trial

Official title:
Feasibility Pilot Study to Evaluate the Safety and Performance of the MEX-CD1 Medical Device in Acute on Chronic Liver Failure (ACLF)

Clinical Trial Summary

The goal of this clinical trial is to test the MEX-CD1 hemodialysis medical device in patients suffering from ACLF. The main questions it aims to answer are: - Is the device safe when used according to the instructions for use? - Does the device work as expected by removing the excess of free copper from the blood? Patients will receive 3 MEX-CD1 Slow Low volume CVVHD within 1 week.

Clinical Trial Description

This study investigates the safety and performance of the MEX-CD1 slow low volume CVVHD device in patients suffering from ACLF. Acute-on-chronic liver failure (ACLF) is defined as a syndrome in patients with acutely decompensated cirrhosis, associated with single or multiple organ failures, and characterized by a high short-term mortality. ACLF is frequently triggered by a precipitating event (alcoholic hepatitis, infection, gastrointestinal haemorrhage) and characterized by an intense systemic inflammatory response driven per pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs) responsible of the development of organs failure through tissues hypoperfusion, immune-mediated tissue damages and mitochondrial dysfunction. Very importantly, ACLF is a very dynamic syndrome that has potential for reversibility. It is hypothesized that the extraction of non-transferrin bound iron (NTBI) could break down the vicious cycle of the excessive inflammatory responses, reduce oxidative stress and inhibit pathogen proliferation in ACLF patients. As a consequence, it is hypothesized that the extraction of NTBI could promote improvement of ACLF grade n to ACLF grade n-1 or no ACLF, at least, it is hypothesized that the extraction of NTBI will stop the progression of ACLF by preventing further organ failures and reducing bacterial infection. Thereby, the extraction of NTBI could restore the eligibility of ACLF patients to liver transplantation, and, with or without liver transplantation, allow an earlier discharge from intensive care and prolong survival. The proposed medical device allows, by combining dialysis to a hyper-chelating colloidal dialysate (MEX-CD1) to specifically extract free iron from the blood. All patients enrolled in this study will receive 3 MEX-CD1 Slow Low volume CVVHD within 1 week. The duration of each MEX-CD1 Slow Low volume CVVHD session is 3h20. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06340269
Study type Interventional
Source Mexbrain
Contact Karen GILLANT
Phone +33674152663
Email Karen.gillant@MEXBRAIN.COM
Status Not yet recruiting
Phase N/A
Start date April 2024
Completion date March 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02906345 - TPE in Septic Patients and Influence on Organ Failure N/A
Completed NCT01937676 - LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting N/A
Not yet recruiting NCT04356300 - Exosome of Mesenchymal Stem Cells for Multiple Organ Dysfuntion Syndrome After Surgical Repaire of Acute Type A Aortic Dissection N/A
Terminated NCT03895853 - Early Metabolic Resuscitation for Septic Shock Phase 2
Recruiting NCT04094428 - Burden, Mortality and Supply Costs in Intensive Care Unit Patients
Recruiting NCT02587273 - The Pharmacokinetics of Fentanyl in Intensive Care Patients Phase 4
Recruiting NCT02265419 - Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of SIRS in Heart Surgery Patients N/A
Completed NCT01810328 - A Validation of a Genomics Based Prognostic in Severe Trauma N/A
Not yet recruiting NCT06371677 - Polish Nationwide Register of Hospitalized Patients in Cardiac Intensive Care Units
Recruiting NCT05182723 - Evaluation of the Effectiveness of Extracorporeal Methods for Removing Mediators of Systemic Inflammation N/A
Completed NCT00257231 - Inflammation and the Host Response to Injury (Trauma)
Recruiting NCT04306419 - Observational Trial on Cytokine Adsorption in Sepsis
Completed NCT02998931 - Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients Phase 3
Not yet recruiting NCT01828372 - Quantification of Drugs and Their Degradation Products N/A
Completed NCT00118664 - Patient Plasma Response and Outcome in Septic Shock With Thrombocytopenia Associated Multiple Organ Failure in Children N/A
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Completed NCT02455180 - Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients Phase 4
Recruiting NCT02095444 - Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection Phase 1/Phase 2
Active, not recruiting NCT02858778 - Timing of Acute Palliative Care Consultation in Critically Ill Patients N/A
Recruiting NCT01363635 - Severe Sepsis/Septic Shock on Admission to the General Surgical ICU